Hypermethylation of the p15INK4b and p16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation

British Journal of Haematology

Volumn 116, Issue 3, 2002, Pages 582-586

  Wang, Jen C ^a   Chen, Wilson ^a   Nallusamy, Selvarany ^a   Chen, Chi ^a   Novetsky, Allan D ^a  

^a MAIMONIDES MEDICAL CENTER   (United States)

Author keywords

AMM (agnogenic myeloid metaplasia); Hypermethylation; MF (idiopathic myelofibrosis); P15; P16

Indexed keywords

PROTEIN P15; PROTEIN P16; CDKN2B PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2B; PROTEIN P16INK4A; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER CHEMOTHERAPY; CELL TRANSFORMATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; LEUKEMIA; METHYLATION; MYELOFIBROSIS; MYELOID METAPLASIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOUTHERN BLOTTING; CPG ISLAND; GENETICS; METHODOLOGY; PRECANCER; TUMOR SUPPRESSOR GENE;

BLOTTING, SOUTHERN; CELL CYCLE PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; CPG ISLANDS; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENES, P16; GENES, TUMOR SUPPRESSOR; HUMANS; LEUKEMIA; METHYLATION; MYELOID METAPLASIA; POLYMERASE CHAIN REACTION; PRECANCEROUS CONDITIONS; TUMOR SUPPRESSOR PROTEINS;

EID: 0036008494     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0007-1048.2001.03319.x     Document Type: Article

References (37)

1. INK4B methylation in acute myeloid leukemia
2. Frequent and selective methylation of p15 and deletion of both p15 and p16 T-cell acute lymphoblastic leukemia
3. Novel germline p16 mutation in familial malignant melanoma in southern Sweden
4. Rates of p16 (MTS1) mutations in primary tumors with 9p loss
5. Frequent somatic mutations and homozygous deletion of the p16 (MTS1) gene in pancreatic adenocarcinoma
6. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation
7. INK4b genes as well as neighboring 9p21 markers in sporadic melanoma
8. Mutations in the P53 and RAS family genes are associated with tumor progression of BCR/ABL negative chronic myeloproliferative disorders
9. INK4b gene during tumor progression in a sporadic melanoma patient
10. Methylation of the 5′CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing
11. INK4b gene deletions in primary leukemias
12. p151NK4B is a potential effector of TGF-B-induced cell cycle
13. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers
14. Germline p16 mutations in familial melanoma
15. Deletion of p16 and p15 genes in brain tumors
16. p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma
17. Hypermethylation of the p16 gene in nasopharyngeal carcinoma
18. INK4B Gene abnormalities between initial diagnosis and relapse in children with acute lymphoblastic leukemia
19. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia
20. 5′CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers
21. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
22. INK4b/MTS2 in pediatric acute lymphoblastic leukemia
23. INK4a gene inactivation by deletions, mutations and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas
24. INK4b gene inactivation in acute lymphoblastic leukemia
25. Karyotypic and ras gene mutational analysis in idiopathic myelofibrosis
26. Progressive increases in de novo methylation of CpG islands in bladder cancer
27. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients
28. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
29. Cancer cell cycles
30. INK4A gene in multiple myeloma
31. INK4b gene in myelodysplastic syndrome
32. Hypermethylation of multiple genes in pancreatic adenocarcinoma
33. P16 gene deletions and point mutations in patients with agnogenic myeloid metaplasia (AMM)
34. Blood thrombopoietin, IL-6 and IL-11 levels in patients with agnogenic myeloid metaplasia
35. Low dose 5′-Aza-2′-Deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter Phase II study in elderly patients
36. Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase